CR20190084A - Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéutico de una infección por el virus del vih - Google Patents

Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéutico de una infección por el virus del vih

Info

Publication number
CR20190084A
CR20190084A CR20190084A CR20190084A CR20190084A CR 20190084 A CR20190084 A CR 20190084A CR 20190084 A CR20190084 A CR 20190084A CR 20190084 A CR20190084 A CR 20190084A CR 20190084 A CR20190084 A CR 20190084A
Authority
CR
Costa Rica
Prior art keywords
therapeutic
prophylactic
hiv virus
virus infection
compounds useful
Prior art date
Application number
CR20190084A
Other languages
English (en)
Inventor
Winston C Tse
John O Link
Dimitrios Stefanidis
Scott D Schroeder
Michael Graupe
Roland D Saito
Jennifer R Zhang
Steven J Henry
Charles William Rowe
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59714166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20190084(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CR20190084A publication Critical patent/CR20190084A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
    • C07C317/08—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Abstract

La presente descripción se refiere a un compuesto de Fórmula (Ia), (Ib), (IIa) y (IIb) que son útiles en el tratamiento de una infección viral por Retroviridae incluyendo una infección causada por el virus del VIH
CR20190084A 2016-08-19 2017-08-17 Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéutico de una infección por el virus del vih CR20190084A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662377312P 2016-08-19 2016-08-19
US201762457555P 2017-02-10 2017-02-10
PCT/US2017/047416 WO2018035359A1 (en) 2016-08-19 2017-08-17 Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection

Publications (1)

Publication Number Publication Date
CR20190084A true CR20190084A (es) 2019-05-02

Family

ID=59714166

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190084A CR20190084A (es) 2016-08-19 2017-08-17 Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéutico de una infección por el virus del vih

Country Status (40)

Country Link
US (3) US10071985B2 (es)
EP (3) EP3347352B1 (es)
JP (4) JP6716785B2 (es)
KR (3) KR20200131351A (es)
CN (2) CN111793061A (es)
AU (4) AU2017312102B2 (es)
BR (2) BR122020001791B1 (es)
CA (1) CA3021227C (es)
CL (1) CL2019000415A1 (es)
CO (1) CO2019001379A2 (es)
CR (1) CR20190084A (es)
CY (1) CY1122296T1 (es)
DK (2) DK3597646T3 (es)
DO (1) DOP2019000033A (es)
EC (1) ECSP19011209A (es)
ES (2) ES2746374T3 (es)
FI (1) FI3597646T3 (es)
FR (1) FR22C1063I2 (es)
HK (1) HK1256904B (es)
HR (1) HRP20231018T1 (es)
HU (3) HUE045137T2 (es)
IL (1) IL264644B (es)
JO (1) JOP20180123A1 (es)
LT (3) LT3597646T (es)
MA (2) MA42795B1 (es)
MX (1) MX369307B (es)
MY (1) MY191466A (es)
NL (1) NL301212I2 (es)
NZ (1) NZ750706A (es)
PE (2) PE20190910A1 (es)
PH (1) PH12019500335A1 (es)
PL (2) PL3347352T3 (es)
PT (2) PT3597646T (es)
SA (1) SA519401123B1 (es)
SG (2) SG10201912535VA (es)
SI (2) SI3597646T1 (es)
TW (4) TWI715944B (es)
UY (1) UY37367A (es)
WO (1) WO2018035359A1 (es)
ZA (1) ZA201901430B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2553449T3 (es) 2011-07-06 2015-12-09 Gilead Sciences, Inc. Compuestos para el tratamiento de VIH
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
LT3597646T (lt) 2016-08-19 2023-09-25 Gilead Sciences, Inc. Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai ir terapiniam gydymui
AR112412A1 (es) * 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TWI687415B (zh) * 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
US10836746B2 (en) 2018-02-15 2020-11-17 Gilead Sciences, Inc. Therapeutic compounds
AR114631A1 (es) 2018-02-16 2020-09-30 Gilead Sciences Inc Métodos e intermedios para preparar compuestos de piridina
WO2019246545A1 (en) * 2018-06-21 2019-12-26 Drexel University Small-molecule hiv-1 capsid protein inhibitors and methods using same
TWI814350B (zh) * 2018-07-16 2023-09-01 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
US11958834B2 (en) 2018-08-09 2024-04-16 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP7361766B2 (ja) 2018-09-14 2023-10-16 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤
EP3853228A1 (en) 2018-09-20 2021-07-28 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US20210395262A1 (en) 2018-10-24 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
BR112021007362A2 (pt) 2018-10-24 2021-07-20 VIIV Healthcare UK (No.5) Limited inibidores da replicação do vírus da imunodeficiência humana
US20210393633A1 (en) 2018-10-25 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US20210403465A1 (en) 2018-10-29 2021-12-30 VIIV Healthcare UK (No.5) Limited Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication
WO2020095177A1 (en) 2018-11-05 2020-05-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP3876942A1 (en) 2018-11-05 2021-09-15 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
SG11202107145SA (en) 2019-01-25 2021-08-30 Univ Brown Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
UY38559A (es) 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
JP2022531251A (ja) 2019-04-30 2022-07-06 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド ヒト免疫不全ウイルス複製阻害剤
RU2717101C1 (ru) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
US20210323967A1 (en) * 2019-06-19 2021-10-21 Viiv Healthcare Uk (No. 5) Limited Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
EP4038064B1 (en) 2019-10-01 2024-02-21 VIIV Healthcare UK (No.5) Limited N-substututed-6-oxo-1,6-dihydropyrimidine-2-yl derivatives as inhibitors of the human immunodeficiency virus replication
WO2021064571A1 (en) 2019-10-01 2021-04-08 VIIV Healthcare UK (No.5) Limited N-substituted-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl derivatives as inhibitors of the human immunodeficiency virus replication
TW202128648A (zh) 2019-10-04 2021-08-01 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑
EP4041729B1 (en) 2019-10-08 2023-09-27 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
TW202133846A (zh) 2019-11-26 2021-09-16 美商基利科學股份有限公司 預防hiv之蛋白殼抑制劑
TW202133858A (zh) 2019-11-28 2021-09-16 日商鹽野義製藥股份有限公司 以組合整合酶阻礙劑及抗ｈｉｖ藥為特徵之ｈｉｖ感染症的預防及治療用醫藥
WO2021104413A1 (zh) * 2019-11-29 2021-06-03 江苏恒瑞医药股份有限公司 稠合吡啶环衍生物、其制备方法及其在医药上的应用
CN116098917A (zh) * 2020-02-27 2023-05-12 河南真实生物科技有限公司 核苷类化合物在治疗冠状病毒感染性疾病中的用途
JP2023517312A (ja) 2020-03-06 2023-04-25 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド ヒト免疫不全ウイルスの複製阻害剤
CA3170536A1 (en) 2020-03-06 2021-09-10 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
CN115605493A (zh) 2020-03-20 2023-01-13 吉利德科学公司（Us） 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法
CN115397424A (zh) 2020-04-15 2022-11-25 Viiv保健英国第五有限公司 人类免疫缺陷病毒复制的抑制剂
WO2021236944A1 (en) 2020-05-21 2021-11-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
CA3181690A1 (en) 2020-06-25 2021-12-30 Chienhung CHOU Capsid inhibitors for the treatment of hiv
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CA3195799A1 (en) 2020-11-11 2022-05-19 Stephen R. Martin Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies
TW202237146A (zh) 2021-01-25 2022-10-01 美商布里生物科學股份有限公司 使用腺苷衍生物及衣殼抑制劑之hiv組合療法
WO2022247942A1 (zh) 2021-05-28 2022-12-01 江苏恒瑞医药股份有限公司 一种稠合吡啶环衍生物的可药用盐、晶型及其制备方法
KR20230018690A (ko) 2021-07-30 2023-02-07 (주) 에빅스젠 둥근이질풀 추출물을 유효성분으로 포함하는, 바이러스성 질환 치료 및 개선용 조성물
KR20230019059A (ko) 2021-07-30 2023-02-07 (주) 에빅스젠 연전초 추출물을 유효성분으로 포함하는, 바이러스성 질환 완화 및 개선용 조성물
WO2023102523A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
US11787825B2 (en) 2021-12-03 2023-10-17 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
US20230203071A1 (en) * 2021-12-03 2023-06-29 Zhimin Du Therapeutic compounds for hiv virus infection
TW202400172A (zh) 2022-04-06 2024-01-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20240034724A1 (en) 2022-07-01 2024-02-01 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
WO2024044477A1 (en) 2022-08-26 2024-02-29 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
JP3347723B2 (ja) 1990-06-13 2002-11-20 グラツィエル，アーノルド 含リンプロドラッグ
DE10399025I2 (de) 1990-09-14 2007-11-08 Acad Of Science Czech Republic Wirkstoffvorläufer von Phosphonaten
JP4357293B2 (ja) 2001-06-27 2009-11-04 スミスクライン ビーチャム コーポレーション ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
AU2002316437A1 (en) 2001-06-27 2003-03-03 Smithkline Beecham Corporation Pyrrolidines as dipeptidyl peptidase inhibitors
ATE355064T1 (de) 2001-10-26 2006-03-15 Angeletti P Ist Richerche Bio Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
US20040186151A1 (en) 2003-02-12 2004-09-23 Mjalli Adnan M.M. Substituted azole derivatives as therapeutic agents
PT1628685E (pt) 2003-04-25 2011-03-16 Gilead Sciences Inc Análogos de fosfonatos antivirais
RU2006134002A (ru) 2004-02-27 2008-04-10 Шеринг Корпорейшн (US) Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
RS51799B (en) 2004-07-27 2011-12-31 Gilead Sciences Inc. NUCLEOSIDE-PHOSPHONATE CONJUGATES AS HIV AGENTS
US8067587B2 (en) 2005-07-28 2011-11-29 Lenroc Company Process for the production of monoalkali metal cyanurates
JP2009503069A (ja) 2005-08-05 2009-01-29 アストラゼネカ アクチボラグ 三環式ベンゾイミダゾール類、および代謝性グルタミン酸塩受容体のモジュレータとしてのそれらの使用
AU2006325754B2 (en) 2005-12-14 2012-04-12 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors
DK2010493T3 (en) 2006-04-12 2016-05-02 Merck Sharp & Dohme PYRIDYLAMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS
US7647464B2 (en) 2006-04-28 2010-01-12 At&T Intellectual Property, I,L.P. Methods, systems, and products for recording media to a restoration server
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
US8124811B2 (en) * 2007-03-20 2012-02-28 Allylix, Inc. Fragrance and methods for production of 5-epi-β-vetivone, 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-2,6-dien-8-one, and 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-1,6-dien-8-one
JP5465667B2 (ja) 2007-06-29 2014-04-09 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス化合物
JP5433573B2 (ja) 2007-07-19 2014-03-05 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ 抗ウイルス剤としての大環状化合物
CA2702126A1 (en) 2007-10-24 2009-04-30 Merck Sharp & Dohme Corp. Heterocycle amide t-type calcium channel antagonists
MX2010005334A (es) 2007-11-16 2010-05-27 Boehringer Ingelheim Int Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
ATE543811T1 (de) 2008-03-13 2012-02-15 Bristol Myers Squibb Co Pyridazinderivate als faktor-xia-inhibitoren
AR074506A1 (es) 2008-12-09 2011-01-19 Gilead Sciences Inc Moduladores de los receptores tipo toll
JP2012518431A (ja) 2009-02-25 2012-08-16 ビッグテック プライベート リミテッド チクングニア検出用のプローブおよびプライマー
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
WO2011139637A1 (en) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Small-molecule modulators of hiv-1 capsid stability and methods thereof
WO2011143772A1 (en) 2010-05-21 2011-11-24 Boehringer Ingelheim International Gmbh Inhibitors of hiv replication
US9296758B2 (en) 2010-07-02 2016-03-29 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as HIV antiviral compounds
JP5984218B2 (ja) 2010-07-02 2016-09-06 ギリアード サイエンシーズ， インコーポレイテッド Ａｉｄｓを処置するためのナフト−２−イル酢酸誘導体
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
PL3290415T3 (pl) 2011-03-23 2021-07-19 Trevena, Inc. Ligandy receptora opioidowego oraz sposoby ich stosowania i wytwarzania
US9006229B2 (en) 2011-04-21 2015-04-14 Gilead Sciences, Inc. Benzothiazole compounds and their pharmaceutical use
ES2553449T3 (es) 2011-07-06 2015-12-09 Gilead Sciences, Inc. Compuestos para el tratamiento de VIH
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
EP2794613B1 (en) 2011-12-20 2017-03-29 Boehringer Ingelheim International GmbH Condensed triclyclic compounds as inhibitors of hiv replication
EP3070081B1 (en) 2012-04-20 2018-02-28 Gilead Sciences, Inc. Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection
GB201213087D0 (en) 2012-07-24 2012-09-05 Medical Res Council Inhibition of HIV-1 infection
US9447134B2 (en) 2012-08-17 2016-09-20 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
KR102040007B1 (ko) 2012-12-21 2019-11-05 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
JP6320039B2 (ja) 2012-12-27 2018-05-09 日本たばこ産業株式会社 置換されたスピロピリド［１，２−ａ］ピラジン誘導体及びそのＨＩＶインテグラーゼ阻害剤としての医薬用途
TW201443037A (zh) * 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
AU2014205317B2 (en) 2013-01-09 2016-11-24 Gilead Sciences, Inc. 5-membered heteroaryls and their use as antiviral agents
EP2943493B1 (en) 2013-01-09 2017-08-02 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
TWI706945B (zh) 2013-03-01 2020-10-11 美商基利科學股份有限公司 供治療反轉錄病毒科病毒感染之治療性化合物
US20140296266A1 (en) 2013-03-01 2014-10-02 Gilead Sciences, Inc. Therapeutic compounds
GB201312991D0 (en) 2013-07-19 2013-09-04 Isis Innovation Process
JP6466433B2 (ja) 2013-10-24 2019-02-06 ビーブ・ヘルスケア・ユーケイ・（ナンバー５）・リミテッドＶｉｉＶ Ｈｅａｌｔｈｃａｒｅ ＵＫ （Ｎｏ．５） Ｌｉｍｉｔｅｄ ヒト免疫不全ウイルス複製の阻害剤
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
EP3186239B1 (en) * 2014-08-29 2018-10-10 Gilead Sciences, Inc. Antiretroviral agents
US9855230B2 (en) 2014-09-09 2018-01-02 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
TW202237569A (zh) 2014-12-24 2022-10-01 美商基利科學股份有限公司 喹唑啉化合物
RU2017138549A (ru) 2015-04-23 2019-05-23 ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД Ингибиторы репликации вируса иммунодефицита человека
CA2983162A1 (en) 2015-04-23 2016-10-27 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
DK3191470T3 (en) * 2015-07-06 2019-04-15 Gilead Sciences Inc COT MODULATORS AND METHODS OF USING THEREOF
US10171985B1 (en) 2015-07-22 2019-01-01 Ginko LLC Method and apparatus for data sharing
LT3597646T (lt) 2016-08-19 2023-09-25 Gilead Sciences, Inc. Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai ir terapiniam gydymui
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
UY37710A (es) 2017-05-02 2018-11-30 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih

Also Published As

Publication number Publication date
JOP20180123A1 (ar) 2019-01-30
FR22C1063I2 (fr) 2023-12-15
CN111793061A (zh) 2020-10-20
DK3597646T3 (da) 2023-09-04
JP2019528280A (ja) 2019-10-10
AU2021221855B2 (en) 2023-08-31
KR102180740B1 (ko) 2020-11-20
UY37367A (es) 2018-03-23
HRP20231018T1 (hr) 2023-12-08
SI3597646T1 (sl) 2023-10-30
ES2954514T3 (es) 2023-11-22
SG11201808944QA (en) 2018-11-29
BR122020001791B1 (pt) 2022-01-25
AU2021221855A1 (en) 2021-09-23
ES2746374T3 (es) 2020-03-05
AU2020202331B2 (en) 2021-05-27
KR20230011471A (ko) 2023-01-20
PL3597646T3 (pl) 2023-12-11
EP3597646B1 (en) 2023-06-21
CN109890808B (zh) 2020-08-07
LT3347352T (lt) 2019-08-12
AU2020202331C1 (en) 2021-08-26
MX369307B (es) 2019-11-05
HUS2200053I1 (hu) 2023-01-28
MX2018012905A (es) 2019-01-30
US20180370950A1 (en) 2018-12-27
AU2023271739A1 (en) 2023-12-14
KR20200131351A (ko) 2020-11-23
PE20190910A1 (es) 2019-06-26
EP4265299A3 (en) 2024-01-17
AU2020202331A1 (en) 2020-04-23
HK1256904B (zh) 2020-07-17
WO2018035359A1 (en) 2018-02-22
SG10201912535VA (en) 2020-02-27
US20180051005A1 (en) 2018-02-22
CA3021227A1 (en) 2018-02-22
IL264644B (en) 2019-09-26
ECSP19011209A (es) 2019-02-28
PH12019500335A1 (en) 2019-11-11
TW201922711A (zh) 2019-06-16
JP2021008516A (ja) 2021-01-28
BR112018071678B1 (pt) 2021-01-26
TW201811327A (zh) 2018-04-01
EP4265299A2 (en) 2023-10-25
BR112018071678A2 (pt) 2019-02-19
CL2019000415A1 (es) 2019-06-21
DK3347352T3 (da) 2019-08-26
CN109890808A (zh) 2019-06-14
JP6716785B2 (ja) 2020-07-01
TW202342449A (zh) 2023-11-01
NL301212I1 (es) 2023-01-12
DOP2019000033A (es) 2019-03-15
TWI664966B (zh) 2019-07-11
JP2020111592A (ja) 2020-07-27
HUE045137T2 (hu) 2019-12-30
CY1122296T1 (el) 2021-01-27
NZ750706A (en) 2020-07-31
AU2017312102B2 (en) 2020-03-05
SI3347352T1 (sl) 2019-08-30
MY191466A (en) 2022-06-28
EP3597646A1 (en) 2020-01-22
TW202138365A (zh) 2021-10-16
PE20211427A1 (es) 2021-08-03
MA42795A (fr) 2019-07-03
SA519401123B1 (ar) 2022-11-09
NL301212I2 (nl) 2023-04-06
US10071985B2 (en) 2018-09-11
EP3347352A1 (en) 2018-07-18
HUE063811T2 (hu) 2024-02-28
LT3597646T (lt) 2023-09-25
CO2019001379A2 (es) 2019-02-19
FR22C1063I1 (fr) 2023-02-03
US20200262815A1 (en) 2020-08-20
EP3347352B1 (en) 2019-07-03
PT3597646T (pt) 2023-09-11
AU2017312102A1 (en) 2019-03-07
KR20190039431A (ko) 2019-04-11
LTPA2023501I1 (es) 2023-02-10
US10654827B2 (en) 2020-05-19
MA42795B1 (fr) 2019-08-30
JP2023011754A (ja) 2023-01-24
PL3347352T3 (pl) 2019-12-31
MA50673A (fr) 2020-08-05
PT3347352T (pt) 2019-09-24
TWI715944B (zh) 2021-01-11
CA3021227C (en) 2020-11-03
FI3597646T3 (fi) 2023-09-07
ZA201901430B (en) 2021-09-29

Similar Documents

Publication Publication Date Title
CR20190084A (es) Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéutico de una infección por el virus del vih
CY1123570T1 (el) Τροποποιητες πυρηνικης πρωτεϊνης ηπατιτιδας β
UY37252A (es) Compuestos para el tratamiento de infección por virus de la hepatitis b
CU20150096A7 (es) Compuestos de amida y composición farmacéutica para el tratamiento de vih
UY37581A (es) Compuestos para el tratamiento de la infección por virus de la hepatitis b
CO2017007355A2 (es) Compuestos derivados de pirazincarbozamida y de pirazincarboxilato para el tratamiento de la infección por el virus de hepatitis b
CR20160241A (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infección por virus de la hepatitis b
CR20160337A (es) Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b
PH12017500207A1 (en) Indoles for use in influenza virus infection
UY35263A (es) Compuestos terapéuticos
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
CL2014003634A1 (es) Inhibidores del virus de la hepatitis c
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
CO7170160A2 (es) Nuevas 6-aminoacido-heteroarildihidropirimidinas para el tratamiento y profilaxis de la infección del virus de la hepatitis b
CL2020000487A1 (es) Agentes antivirales contra la hepatitis b.
ECSP12012106A (es) Terapia antiviral
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
SV2017005381A (es) Compuestos de imidazopiridazina
CL2020002254A1 (es) Régimen posológico del modulador del ensamblaje de la cápside.
AR109364A1 (es) Compuestos antivirales
EA201990295A1 (ru) Терапевтические соединения, которые можно применять для профилактического или терапевтического лечения инфекции вирусом вич
EA201691835A1 (ru) Аллостерические модуляторы капсидного белка гепатита в